Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$1.28
$0.75
$26.18
$7.26M1.27811,695 shs119,800 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$4.14
-2.6%
$3.89
$1.96
$10.00
$282.22M0.58834,700 shs358,779 shs
Metacrine, Inc. stock logo
MTCR
Metacrine
$0.58
$0.57
$0.30
$0.59
$24.75M-0.73225,834 shs83,889 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.74
+5.8%
$1.67
$1.15
$3.47
$11.47M-0.3422,254 shs2,653 shs
Savara Inc. stock logo
SVRA
Savara
$2.39
+3.9%
$2.49
$1.89
$5.11
$397.52M0.311.27 million shs1.08 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-2.59%+5.21%-8.00%+38.93%+117.89%
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00%0.00%0.00%0.00%0.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+3.58%+2.06%-3.61%+19.66%-47.90%
Savara Inc. stock logo
SVRA
Savara
+3.91%+11.94%+8.64%-18.15%-50.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.8739 of 5 stars
3.51.00.00.03.33.30.6
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.2441 of 5 stars
3.05.00.04.62.00.01.3
Savara Inc. stock logo
SVRA
Savara
2.1324 of 5 stars
3.30.00.00.02.43.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00
N/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00262.32% Upside
Metacrine, Inc. stock logo
MTCR
Metacrine
0.00
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00188.18% Upside
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60134.31% Upside

Current Analyst Ratings Breakdown

Latest SVRA, NERV, ADMP, CRVS, and MTCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
5/20/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$12.00 ➝ $11.00
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$4.76M0.00N/AN/A($1.26) per share0.00
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/A$1.36 per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.22 per share7.85($3.67) per shareN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
Metacrine, Inc. stock logo
MTCR
Metacrine
-$62.21M-$1.03N/AN/AN/A-84.88%-59.33%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.12N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)

Latest SVRA, NERV, ADMP, CRVS, and MTCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Metacrine, Inc. stock logo
MTCR
Metacrine
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/A
0.23
0.19
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
Metacrine, Inc. stock logo
MTCR
Metacrine
0.34
12.15
12.15
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91

Institutional Ownership

CompanyInstitutional Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
38.55%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Metacrine, Inc. stock logo
MTCR
Metacrine
37.72%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Savara Inc. stock logo
SVRA
Savara
87.93%

Insider Ownership

CompanyInsider Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
1.30%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
Metacrine, Inc. stock logo
MTCR
Metacrine
13.80%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
8.60%
Savara Inc. stock logo
SVRA
Savara
5.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
119.36 million9.24 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million48.74 millionOptionable
Metacrine, Inc. stock logo
MTCR
Metacrine
1042.57 million36.70 millionNot Optionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
9N/AN/ANot Optionable
Savara Inc. stock logo
SVRA
Savara
20172.84 million163.63 millionOptionable

Recent News About These Companies

Savara Independent Director Acquires 177% More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamis Pharmaceuticals stock logo

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$4.14 -0.11 (-2.59%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.16 +0.02 (+0.48%)
As of 07/11/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Metacrine stock logo

Metacrine NASDAQ:MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.74 +0.10 (+5.79%)
Closing price 07/11/2025 03:51 PM Eastern
Extended Trading
$1.73 -0.01 (-0.29%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Savara stock logo

Savara NASDAQ:SVRA

$2.39 +0.09 (+3.91%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.39 0.00 (0.00%)
As of 07/11/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.